No Data
No Data
Express News | Incyte and Syndax Announce U.S. FDA Approval of Niktimvo™ (Axatilimab-Csfr) for the Treatment of Chronic Graft-Versus-Host Disease (Gvhd)
Incyte Insider Sold Shares Worth $703,793, According to a Recent SEC Filing
Express News | Incyte Corp Shares Down 1% in Volume Spike After FDA Approves Graft-Versus-Host Disease Drug
Express News | FDA Approves Axatilimab-CSFR For Treatment Of Chronic Graft-Versus-Host Disease
Express News | FDA Approves Axatilimab-Csfr for Chronic Graft-Versus-Host Disease
Do Options Traders Know Something About Incyte (INCY) Stock We Don't?
No Data
73296040 : bullish?
Trytosaveabit OP 73296040 : It’s great news! FDA approval